title: [Lung cancer: 25-year experience with surgical and combined treatment].
abstract: Data on surgical and combined treatment of 950 patients with non-small lung cancer are evaluated. After combined treatment of lung cancer stage III using intraoperative radiotherapy and adjuvant chemotherapy or radiosensitization, recurrence-free survival rose to 13.3 +/- 2.3 and 23.0 +/- 1.1 months, respectively; 5-year overall survival--32.8 +/- 3.2% and 40.3 +/- 4.2% respectively. Compare with 10.4 +/- 1.3 months and 20.8 +/- 8.5%, respectively, for surgery alone. Despite the prejudice against preoperative radiotherapy, postoperative one administered in TTD of 40-60 Gy (median 55 Gy) may be recommended for treatment of lung cancer spreading to mediastinal lymph nodes.
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Dobrodeev
authors.forename: A A
authors.initials: AA
authors.lastname: Zav'ialov
authors.forename: S A
authors.initials: SA
authors.lastname: Tuzikov
authors.forename: S V
authors.initials: SV
authors.lastname: Miller
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
chemical_list: D011838:Radiation-Sensitizing Agents